Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
DSCI's Cash to Debt is ranked higher than
85% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.30 vs. DSCI: No Debt )
DSCI' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.93
DSCI's Equity to Asset is ranked higher than
98% of the 303 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. DSCI: 0.93 )
DSCI' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.94
Current: 0.93

0.28
0.94
Interest Coverage No Debt
DSCI's Interest Coverage is ranked higher than
90% of the 206 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. DSCI: No Debt )
DSCI' s 10-Year Interest Coverage Range
Min: 0.23   Max: 9999.99
Current: No Debt

0.23
9999.99
F-Score: 4
Z-Score: 11.33
M-Score: -2.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -35.85
DSCI's Operating margin (%) is ranked higher than
54% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.78 vs. DSCI: -35.85 )
DSCI' s 10-Year Operating margin (%) Range
Min: -34.85   Max: 4.71
Current: -35.85

-34.85
4.71
Net-margin (%) -35.14
DSCI's Net-margin (%) is ranked higher than
56% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.12 vs. DSCI: -35.14 )
DSCI' s 10-Year Net-margin (%) Range
Min: -34.85   Max: 2.4
Current: -35.14

-34.85
2.4
ROE (%) -20.23
DSCI's ROE (%) is ranked higher than
59% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.58 vs. DSCI: -20.23 )
DSCI' s 10-Year ROE (%) Range
Min: -77.42   Max: 5.82
Current: -20.23

-77.42
5.82
ROA (%) -18.80
DSCI's ROA (%) is ranked higher than
57% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.35 vs. DSCI: -18.80 )
DSCI' s 10-Year ROA (%) Range
Min: -38.98   Max: 4.07
Current: -18.8

-38.98
4.07
ROC (Joel Greenblatt) (%) -132.20
DSCI's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.02 vs. DSCI: -132.20 )
DSCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -287.5   Max: 15.79
Current: -132.2

-287.5
15.79
Revenue Growth (%) -19.40
DSCI's Revenue Growth (%) is ranked higher than
54% of the 280 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.20 vs. DSCI: -19.40 )
DSCI' s 10-Year Revenue Growth (%) Range
Min: -40.2   Max: 11.5
Current: -19.4

-40.2
11.5
EPS Growth (%) 53.10
DSCI's EPS Growth (%) is ranked higher than
95% of the 236 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. DSCI: 53.10 )
DSCI' s 10-Year EPS Growth (%) Range
Min: -29.7   Max: 122.4
Current: 53.1

-29.7
122.4
» DSCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

DSCI Guru Trades in

Q4 2013

DSCI Guru Trades in Q4 2013

Chuck Royce 55,000 sh (New)
» More
Q1 2014

DSCI Guru Trades in Q1 2014

Jim Simons 95,281 sh (New)
Chuck Royce 55,000 sh (unchged)
» More
Q2 2014

DSCI Guru Trades in Q2 2014

Chuck Royce 55,000 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DSCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.40
DSCI's P/B is ranked higher than
90% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. DSCI: 1.40 )
DSCI' s 10-Year P/B Range
Min: 0.5   Max: 7.72
Current: 1.4

0.5
7.72
P/S 2.10
DSCI's P/S is ranked higher than
80% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. DSCI: 2.10 )
DSCI' s 10-Year P/S Range
Min: 0.21   Max: 3.26
Current: 2.1

0.21
3.26
EV-to-EBIT -3.83
DSCI's EV-to-EBIT is ranked higher than
59% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.10 vs. DSCI: -3.83 )
DSCI' s 10-Year EV-to-EBIT Range
Min: 2.1   Max: 663.7
Current: -3.83

2.1
663.7
Current Ratio 12.84
DSCI's Current Ratio is ranked higher than
96% of the 238 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.92 vs. DSCI: 12.84 )
DSCI' s 10-Year Current Ratio Range
Min: 1.05   Max: 15.92
Current: 12.84

1.05
15.92
Quick Ratio 10.91
DSCI's Quick Ratio is ranked higher than
96% of the 238 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. DSCI: 10.91 )
DSCI' s 10-Year Quick Ratio Range
Min: 0.4   Max: 13.56
Current: 10.91

0.4
13.56

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.67
DSCI's Price/Net Cash is ranked higher than
97% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. DSCI: 2.67 )
DSCI' s 10-Year Price/Net Cash Range
Min: 1.68   Max: 272
Current: 2.67

1.68
272
Price/Net Current Asset Value 2.25
DSCI's Price/Net Current Asset Value is ranked higher than
97% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. DSCI: 2.25 )
DSCI' s 10-Year Price/Net Current Asset Value Range
Min: 1.06   Max: 485
Current: 2.25

1.06
485
Price/Tangible Book 1.78
DSCI's Price/Tangible Book is ranked higher than
90% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.22 vs. DSCI: 1.78 )
DSCI' s 10-Year Price/Tangible Book Range
Min: 0.42   Max: 15.27
Current: 1.78

0.42
15.27
Price/DCF (Projected) 6.36
DSCI's Price/DCF (Projected) is ranked higher than
75% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.31 vs. DSCI: 6.36 )
DSCI' s 10-Year Price/DCF (Projected) Range
Min: 1.12   Max: 23.81
Current: 6.36

1.12
23.81
Price/Median PS Value 3.13
DSCI's Price/Median PS Value is ranked higher than
53% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. DSCI: 3.13 )
DSCI' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 7.97
Current: 3.13

0.12
7.97
Earnings Yield (Greenblatt) 1.50
DSCI's Earnings Yield (Greenblatt) is ranked higher than
53% of the 260 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. DSCI: 1.50 )
DSCI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 48.5
Current: 1.5

0.2
48.5
Forward Rate of Return (Yacktman) -5.24
DSCI's Forward Rate of Return (Yacktman) is ranked higher than
65% of the 258 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.55 vs. DSCI: -5.24 )
DSCI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -87.5   Max: 6.6
Current: -5.24

-87.5
6.6

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Derma Sciences, Inc., was incorporated under the laws of Colorado on September 10, 1984. On June 3, 1996, it changed its state of domicile to Pennsylvania and on September 14, 2012, it changed its state of domicile to Delaware. The Company is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products. The Company has one pharmaceutical wound care product under development that has completed its Phase 2 study and has initiated its Phase 3 study in 2013. The Company maintains manufacturing facilities in Toronto, Canada and Nantong, China and an established network of third party suppliers for its products. Its products are sold through distributors to health care providers such as wound care centers, extended care facilities, acute care facilities, home health care agencies and physicians' offices. Some of its products are sold through retail channels. The Company markets its products through direct sales representatives in the United States, Canada and the United Kingdom, and through independent distributors within other select international markets. Its advanced wound care includes moist, occlusive dressing such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressing, cleansers and its proprietary Dermagran products. Its products include MEDIHONEY, TCC-EZ, XTRASORB, BIOGUARD, and ALGICELL AG. Its traditional wound care line consists of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices. It also manufactures and market adhesive bandages and related first aid products for the medical, industrial, private label and retail markets. It markets a line of wound closure strips, nasal tube fasteners and a variety of catheter fasteners to doctors, clinics, nursing homes, hospitals and other institutions. The Company competes with companies including ASO and Dynerex, Convatec, Smith & Nephew, Molnlycke and Systagenix, Johnson & Johnson, 3M and Medline.
» More Articles for DSCI

Headlines

Articles On GuruFocus.com
Derma Sciences Inc. Reports Operating Results (10-Q) Nov 12 2010 
Derma Sciences Inc. Reports Operating Results (10-Q) May 12 2010 

More From Other Websites
DERMA SCIENCES, INC. Financials Aug 20 2014
Derma Sciences to Present at Canaccord Genuity 34th Annual Growth Conference on August 14 Aug 12 2014
Derma Sciences Inc Earnings Call scheduled for 11:00 am ET today Aug 07 2014
Derma Sciences Reports Second Quarter Financial Results Aug 07 2014
Q2 2014 Derma Sciences, Inc. Earnings Release - Before Market Open Aug 07 2014
DERMA SCIENCES, INC. Files SEC form 10-Q, Quarterly Report Aug 06 2014
Derma Sciences to Hold Second Quarter Financial Results Conference Call on August 7th Aug 01 2014
Derma Sciences CEO Discusses Continued Growth of MEDIHONEY® at Comvita Annual Meeting of... Jul 25 2014
Derma Sciences announces Veterans Administration adds AMNIOEXCEL® to its Federal Supply Schedule Jul 22 2014
Derma (DSCI) is in Overbought Territory: What's Next? Jun 19 2014
Derma Sciences, Inc. to Webcast June 17th Analyst Day Jun 13 2014
[video] Derma Sciences CEO: Medihoney Sales Sweet and Getting Sweeter May 29 2014
DERMA SCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... May 23 2014
Derma Sciences management to meet with Oppenheimer May 22 2014
Derma Sciences' (DSCI) CEO Ed Quilty on Q1 2014 Results - Earnings Call Transcript May 09 2014
Derma Sciences affirms FY14 net sales view $92M, consensus $91.78M May 08 2014
Derma Sciences reports Q1 EPS (46c), consensus (32c) May 08 2014
Derma Sciences Reports First Quarter Financial Results May 08 2014
DERMA SCIENCES, INC. Files SEC form 10-Q, Quarterly Report May 07 2014
Derma Sciences to Present at Sidoti Semiannual Micro-Cap Conference on May 9 May 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK